Chromatin profiles of CLL

Chromatin accessibility maps of chronic lymphocytic leukemia

Chromatin profiles of CLL

Chronic lymphocytic leukemia (CLL) is a genetically, epigenetically, and clinically heterogeneous disease, with relatively few genetic alterations. The Bruton tyrosine kinase inhibitor ibrutinib provides effective treatment for the vast majority of CLL patients, and while not curative, ibrutinib provides a potential avenue to pharmacologically exploit vulnerabilities of this disease.

Genome-wide chromatin accessibility profiling is used to define the underlying regulatory programs of epigenome deregulation in CLL. Enriched with thorough clinical annotation, flow cytometry, CHIPmentation, transcriptomic profiling and/or chemosensitivity profiling, these datasets enable the dissection of patient-to-patient variability, the identification of consistent regulatory programs shared across patients and its dynamics during ibrutinib treatment course, and the discovery of potential new drug vulnerabilities.

Publications

Chromatin mapping and single-cell immune profiling defines the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia

Chromatin mapping and single-cell immune profiling defines the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia

Rendeiro AF*, Krausgruber T*, Fortelny N, Zhao F, Penz T, Farlik M, Schuster LC, Kuchler A, Tasnády S, Réti M, Zoltán M, Alpar D*, Bödör C*, Schmidl C*, Bock C*

Nature Communications  11, 577 (2020). DOI: 10.1038/s41467-019-14081-6

Open access logo
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

Schmidl C*, Vladimer GI*, Rendeiro AF*, Schnabl S*, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M*, Superti-Furga G*, Jäger U*, Bock C*

Nature Chemical Biology  15, 232-240 (2019). DOI: 10.1038/s41589-018-0205-2

epmc-logo-small.png
Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

Rendeiro AF*, Schmidl C*, Strefford JC*, Walewska R, Davis Z, Farlik M, Oscier D, Bock C*

Nature Communications  7, 11938 (2016). DOI: 10.1038/ncomms11938

Open access logo

* shared first or shared senior authorship